SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid speculation that the U.S. government might take equity stakes in quantum computing companies, though some sources refute active negotiations. Community discussions revolve around the potential implications of government funding and whether this signals long-term growth or a short-term pump. Bullish investors believe this move would validate quantum computing's future, while bears express concerns about overvaluation and the source of the news.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amid reports and speculation around potential government equity stakes in quantum computing firms, sparking debates about the long-term implications and strategic importance of these investments. Community members are weighing the significance of potential deals versus existing funding, while also discussing the volatile price action and potential for a short squeeze. The broader context involves the race for quantum supremacy and the potential for government involvement in frontier technologies.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is seeing active discussion, with community members reacting to recent performance and analyst target price adjustments. Some traders are weighing short-term opportunities, while others debate the company's long-term vision, particularly around AI and full self-driving, as well as Musk's leadership and proposed compensation.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors digest news regarding preliminary Q1 revenue falling short of guidance, attributed to design upgrades pushing revenue to Q2. Despite the setback, the company reiterated its full-year revenue guidance, sparking debate among investors about management's credibility and the potential for future growth in the AI sector. Community discussions revolve around whether this is a buying opportunity or a sign of deeper issues within the company.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending amid ongoing debate regarding the likelihood of EMA approval for its Alzheimer's drug, Blarcamesine. Community discussions focus on analyst opinions and the potential for a short squeeze, particularly regarding a recent analyst "hit piece" that some believe is FUD to cover shorts. Traders are weighing the drug's prospects against safety data and potential market competition.

Integer Holdings Corp. engages in the manufacture and development of medical devices and components. The firm has the following product lines: Cardio and Vascular, Cardiac Rhythm Management and Neuromodulation, and Other Markets. The company was founded by Wilson Greatbatch in 1970 and is headquartered in Plano, TX.

Integer Holdings Corp

Integer Holdings is trending as the stock experiences a significant drop following weaker-than-expected financial guidance for 2025 and preliminary guidance for 2026. The community is actively discussing whether the selloff is an overreaction and if $ITGR presents a short squeeze or swing trade opportunity, with some expressing concerns about the company's debt and others seeing a buying opportunity.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as investors assess its operational momentum, particularly in hybrid cloud and AI, following recent Q3 results. The community is discussing its reinvention as an AI player and comparing it to other tech giants like Tesla and Netflix. A key point of interest is the company's infrastructure and automation growth, as well as its progress in quantum computing.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

VZ is trending as community members discuss its oversold conditions and potential for a recovery, with some highlighting its attractive dividend yield. Discussions also focus on the company's earnings performance and potential impact of the new CEO's strategies. Broader telecom sector dynamics, including competition and spectrum acquisitions, are influencing the conversation.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

VTYX is trending as positive trial results spark optimism around the stock's potential, with some community members speculating about a possible Sanofi buyout. Bullish investors are actively discussing potential price upgrades and high price targets. However, some traders remain cautious, pointing to potential short attacks and the possibility of a retracement.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending amid reports and speculation regarding potential U.S. government funding and even an equity stake in quantum computing firms. Community discussions revolve around the validity and impact of these reports, with some skeptical about the size and implications of any potential deal, while others see it as a bullish sign of government support for the sector. The stock's movement is also being heavily debated, with both bulls and bears presenting their arguments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy...

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates

Repare Therapeutics (RPTX) delivered earnings and revenue surprises of +30.36% and -95.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics saw its stock climb in after-hours trading Tuesday after disclosing a global licensing deal with Switzerland-based Debiopharm International for lunresertib, a first-in-class PKMYT1 inhibitor aimed at treating hard-to-tackle solid tumors.The agreement gives Repare a $10 million upfront boost, with the potential to bring in up to $257 million more through clinical, regulatory, and commercial milestones, including $5 million in possible near-term payouts.&nbsp;Repare will also earn single-digit royalties on future global net sales.<a href="https://stocktwits.com/symbol/RPTX">RPTX’s stock</a> closed Monday down 8.9% at $1.43, but rebounded 22.4% in after-hours trading to $1.75.The agreement builds on an existing collaboration between the two companies that explored the synergy of lunresertib with Debiopharm’s Debio 0123, a selective WEE1 inhibitor.&nbsp;As part of the deal, Debiopharm will take over sponsorship of the Mythic trial and assume all development activities related to lunresertib moving forward.Repare remains on track to report initial data from two ongoing Phase 1 trials—the Lions trial for its PLK4 inhibitor RP-1664 and the Polar trial for its Polθ ATPase inhibitor RP-3467—in the second half of 2025.As of March 31, Repare had $124.2 million in cash and marketable securities on hand, which it says should be enough to fund its operations through 2027.&nbsp;The company reported a net loss of $0.71 per share in the first quarter, swinging from a profit of $0.30 per share in the same period last year.&nbsp;Repare has said it continues to explore strategic alternatives across its pipeline, including out-licensing and partnerships.On Stocktwits, retail sentiment for RPTX was ‘extremely bullish’ amid ‘extremely high’ message volume.One Stocktwits user expressed optimism about their position in the stock, noting an entry point at $1.62 with 10,000 shares and indicating confidence heading into the pre-market session.&nbsp;<stembedurl>https://stocktwits.com/TheThroatSlasher/message/621090644</stembedurl>Another user encouraged buying, citing the stock’s after-hours gain.<stembedurl>https://stocktwits.com/Eelmm842/message/621076455</stembedurl>RPTX’s stock has risen 8.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Repare Therapeutics (RPTX) disclosed a global licensing deal with Switzerland-based Debiopharm International. (Photo credit: Getty Images)

Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In

Repare Therapeutics saw its stock climb in after-hours trading Tuesday after disclosing a global licensing deal with Switzerland-based Debiopharm International for lunresertib

Equity

The deal builds on an existing collaboration around lunresertib and hands development control to Debiopharm, allowing Repare to focus on its Phase 1 trials for RP-1664 and RP-3467.

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment of resources and a re-prioritization of its...

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive data from its MYTHIC Phase 1 gynecologic expansion...

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the...

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been...

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2024...

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data highlighting the benefits of its individualized...

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

RPTX
Repare Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RPTX News

RPTXRepare Therapeutics Inc